FR2497099A1 - Production de facteur leucopoietique humain - Google Patents
Production de facteur leucopoietique humain Download PDFInfo
- Publication number
- FR2497099A1 FR2497099A1 FR8124363A FR8124363A FR2497099A1 FR 2497099 A1 FR2497099 A1 FR 2497099A1 FR 8124363 A FR8124363 A FR 8124363A FR 8124363 A FR8124363 A FR 8124363A FR 2497099 A1 FR2497099 A1 FR 2497099A1
- Authority
- FR
- France
- Prior art keywords
- cells
- human
- flh
- factor
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 23
- 230000001735 leucopoietic effect Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 37
- 241001465754 Metazoa Species 0.000 claims abstract description 33
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 27
- 210000005260 human cell Anatomy 0.000 claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 238000009792 diffusion process Methods 0.000 claims description 7
- 238000011580 nude mouse model Methods 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 4
- 241000700159 Rattus Species 0.000 claims description 4
- 241000699800 Cricetinae Species 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 239000002158 endotoxin Substances 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 239000003226 mitogen Substances 0.000 claims description 3
- 230000000050 nutritive effect Effects 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 2
- 241000700199 Cavia porcellus Species 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 241000272201 Columbiformes Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 150000002642 lithium compounds Chemical class 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- RCMPDPZUFZOHKM-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;sulfuric acid Chemical compound OS(O)(=O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O RCMPDPZUFZOHKM-BTVCFUMJSA-N 0.000 claims 1
- 210000000712 G cell Anatomy 0.000 claims 1
- 101000851434 Homo sapiens Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000396377 Tranes Species 0.000 claims 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 1
- 150000001767 cationic compounds Chemical class 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000007796 conventional method Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 230000036046 immunoreaction Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 102000016605 B-Cell Activating Factor Human genes 0.000 description 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101000935623 Homo sapiens 3'(2'),5'-bisphosphate nucleotidase 1 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 102000050103 human PIP Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000017830 lymphoblastoma Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/948—Microorganisms using viruses or cell lines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP55185732A JPS6030654B2 (ja) | 1980-12-31 | 1980-12-31 | ヒトコロニ−刺激因子の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2497099A1 true FR2497099A1 (fr) | 1982-07-02 |
| FR2497099B1 FR2497099B1 (cg-RX-API-DMAC7.html) | 1984-11-09 |
Family
ID=16175883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8124363A Granted FR2497099A1 (fr) | 1980-12-31 | 1981-12-29 | Production de facteur leucopoietique humain |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4621050A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS6030654B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR870001149B1 (cg-RX-API-DMAC7.html) |
| CH (1) | CH649786A5 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2497099A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2092159B (cg-RX-API-DMAC7.html) |
| IT (1) | IT1148022B (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS609795B2 (ja) * | 1980-12-11 | 1985-03-13 | 株式会社林原生物化学研究所 | ヒト上皮細胞成長因子の製造方法 |
| AU599572B2 (en) * | 1984-07-06 | 1990-07-26 | Novartis Ag | Lymphokine production and purification |
| JPS61227526A (ja) * | 1984-07-25 | 1986-10-09 | Chugai Pharmaceut Co Ltd | 新規なコロニー刺激因子 |
| UA29377C2 (uk) * | 1984-09-19 | 2000-11-15 | Новартіс Аг | Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів |
| US4968618A (en) * | 1984-11-16 | 1990-11-06 | University Of Florida | Composition and method for promoting growth of granulocytes |
| US4847201A (en) * | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
| EP0209601B1 (en) * | 1985-02-05 | 1993-12-15 | Cetus Oncology Corporation | Recombinant colony stimulating factor-1 |
| US5573930A (en) * | 1985-02-05 | 1996-11-12 | Cetus Oncology Corporation | DNA encoding various forms of colony stimulating factor-1 |
| US6156300A (en) * | 1985-02-05 | 2000-12-05 | Chiron Corporation | Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof |
| US6117422A (en) * | 1985-02-05 | 2000-09-12 | Chiron Corporation | N∇2-CSF-1(long form) and carboxy truncated fragments thereof |
| WO1986004605A1 (fr) * | 1985-02-08 | 1986-08-14 | Chugai Seiyaku Kabushiki Kaisha | Facteur de stimulation de colonies de granulocytes humains |
| US5532341A (en) * | 1985-03-28 | 1996-07-02 | Sloan-Kettering Institute For Cancer Research | Human pluripotent hematopoietic colony stimulating factor |
| EP0238655A4 (en) * | 1985-10-03 | 1989-09-11 | Biogen Nv | POLYPEPTIDES LIKE THE GRANULOCYTE-MACROPHOUS COLONY STIMULATION FACTORS (GM-CSF) AND THEIR METHODS OF PRODUCING LARGE QUANTITIES IN MICROBIAL CELLS. |
| JPH0618778B2 (ja) * | 1985-10-04 | 1994-03-16 | 中外製薬株式会社 | 白血球減少症治療剤 |
| NZ218336A (en) * | 1985-12-09 | 1991-08-27 | Kirin Amgen Inc | Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf) |
| JPH0618780B2 (ja) * | 1986-01-22 | 1994-03-16 | 中外製薬株式会社 | 骨髄性白血病抑制剤 |
| JPH0618779B2 (ja) * | 1986-01-22 | 1994-03-16 | 中外製薬株式会社 | 造血機能回復促進剤 |
| ZA874410B (en) * | 1986-06-24 | 1988-04-27 | Merrell Dow Pharma | Fusion products |
| US5162111A (en) * | 1986-07-30 | 1992-11-10 | Grabstein Kenneth H | Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor |
| JPH0618781B2 (ja) * | 1986-10-18 | 1994-03-16 | 中外製薬株式会社 | 感染症治療剤 |
| JPS63245667A (ja) * | 1987-03-31 | 1988-10-12 | Ube Ind Ltd | 肥満細胞成長活性を有するヒトｉｌ−３産生ヒト細胞および肥満細胞成長活性を有するヒトｉｌ−３の製造方法 |
| US7094400B1 (en) * | 1987-05-01 | 2006-08-22 | Shire Human Genetic Therapies, Inc. | Transkaryotic implantation |
| JPS6439855A (en) * | 1987-08-05 | 1989-02-10 | Nec Corp | Surface acoustic wave device |
| US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| JPH02211748A (ja) * | 1989-02-10 | 1990-08-23 | Nec Eng Ltd | 直交変調回路 |
| US5148267A (en) * | 1989-09-08 | 1992-09-15 | Hewlett-Packard Company | Double heterostructure step recovery diode with internal drift field |
| JPH03241947A (ja) * | 1990-02-20 | 1991-10-29 | Murata Mfg Co Ltd | ４相位相変調器 |
| CA2044468C (en) * | 1990-11-21 | 2006-08-22 | Richard A. Nash | Canine granulocyte macrophage colony stimulating factor |
| US6653134B2 (en) * | 1995-03-28 | 2003-11-25 | Cp Hahnemann University | Isolated stromal cells for use in the treatment of diseases of the central nervous system |
| US6974571B2 (en) * | 1995-03-28 | 2005-12-13 | Thomas Jefferson University | Isolated stromal cells and methods of using the same |
| US6136599A (en) * | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
| US20030044398A1 (en) * | 2001-03-20 | 2003-03-06 | Robl James M. | Methods for producing antibodies in mammals |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2461500A1 (fr) * | 1979-07-20 | 1981-02-06 | Morinaga Milk Industry Co Ltd | Procede de production d'une substance capable de stimuler la proliferation et la differenciation des cellules souches granulopoietiques humaines |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2016015B (en) * | 1978-01-22 | 1982-05-06 | Hayashibara Co | Method of preparing interferon and preparations containing interferon |
| US4242460A (en) * | 1978-12-26 | 1980-12-30 | Chick William L | Cell culture device |
| JPS5598118A (en) * | 1979-01-18 | 1980-07-25 | Hayashibara Takeshi | Preparation of type-2 interferon and drug containing the same |
| US4328207A (en) * | 1979-12-27 | 1982-05-04 | Ken Hayashibara | Process for preparing mouse interferon |
| JPS586475B2 (ja) * | 1980-08-23 | 1983-02-04 | 株式会社 林原生物化学研究所 | ヒト絨毛性性腺刺激ホルモンの製造方法 |
| JPS6045849B2 (ja) * | 1980-08-25 | 1985-10-12 | 林原 健 | ヒトエリトロポエチンの製造方法 |
| JPS585671B2 (ja) * | 1980-08-27 | 1983-02-01 | 株式会社 林原生物化学研究所 | ヒト卵胞刺激ホルモンの製造方法 |
| JPS5743696A (en) * | 1980-08-27 | 1982-03-11 | Hayashibara Biochem Lab Inc | Preparation of human luteinizing hormone |
-
1980
- 1980-12-31 JP JP55185732A patent/JPS6030654B2/ja not_active Expired
-
1981
- 1981-12-22 GB GB8138591A patent/GB2092159B/en not_active Expired
- 1981-12-23 IT IT49993/81A patent/IT1148022B/it active
- 1981-12-28 KR KR1019810005159A patent/KR870001149B1/ko not_active Expired
- 1981-12-29 FR FR8124363A patent/FR2497099A1/fr active Granted
- 1981-12-30 CH CH8352/81A patent/CH649786A5/fr not_active IP Right Cessation
-
1984
- 1984-03-05 US US06/585,617 patent/US4621050A/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2461500A1 (fr) * | 1979-07-20 | 1981-02-06 | Morinaga Milk Industry Co Ltd | Procede de production d'une substance capable de stimuler la proliferation et la differenciation des cellules souches granulopoietiques humaines |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57114525A (en) | 1982-07-16 |
| GB2092159A (en) | 1982-08-11 |
| IT1148022B (it) | 1986-11-26 |
| IT8149993A0 (it) | 1981-12-23 |
| CH649786A5 (fr) | 1985-06-14 |
| FR2497099B1 (cg-RX-API-DMAC7.html) | 1984-11-09 |
| JPS6030654B2 (ja) | 1985-07-17 |
| US4621050A (en) | 1986-11-04 |
| KR870001149B1 (ko) | 1987-06-11 |
| KR830007826A (ko) | 1983-11-07 |
| GB2092159B (en) | 1984-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2497099A1 (fr) | Production de facteur leucopoietique humain | |
| CH650024A5 (fr) | Procede pour la production d'erythropoietine humaine. | |
| FR2495937A1 (fr) | Procede pour la production du facteur de croissance epidermique humain | |
| CH650801A5 (fr) | Procede pour preparer de l'interferon de type ii et preparation contenant de l'interferon de type ii. | |
| CH637831A5 (fr) | Procede de preparation d'interferon et preparation le contenant. | |
| FR2489152A1 (fr) | Production d'hormone humaine stimulant les follicules | |
| FR2495635A1 (fr) | Production d'urokinase humaine | |
| KR860000898B1 (ko) | 인체 융모막성선 자극호르몬(Human Chorionic Gonadotropin)의 제조방법 | |
| FR2556220A1 (fr) | Nouveau lymphokine et anticorps monoclonal specifique de ce lymphokine, leur production et leurs utilisations | |
| FR2489151A1 (fr) | Production d'hormone luteinisante humaine | |
| GB2083826A (en) | Process for the production of human insulin | |
| FR2487852A1 (fr) | Production d'hormone de croissance humaine | |
| FR2615737A1 (fr) | Preparation et utilisation d'interferon-gamma | |
| CH652750A5 (fr) | Production de facteur de croissance humain. | |
| FR2572936A1 (fr) | Nouveau lymphokine et anticorps monoclonal specifique de ce lymphokine, leurs production et utilisations | |
| FR2497102A1 (fr) | Production d'hormone parathyroidienne humaine | |
| CH652749A5 (fr) | Production de calcitonine humaine. | |
| BE873594A (fr) | Interferon et preparation le contenant | |
| JPS6030656B2 (ja) | ヒトｔ細胞増殖因子の製造方法 | |
| CN115109755B (zh) | 敲除Dicer的单核细胞、组合物及其在制备治疗胶质母细胞瘤药物中的应用 | |
| FR2496466A1 (fr) | Production d'hormone lactogene, placentaire, humaine | |
| FR2497101A1 (fr) | Production d'hormone stimulation de la thyroide humaine | |
| CH652745A5 (fr) | Procede pour la production d'hormone adrenocorticotrope humaine. | |
| FR2523155A1 (fr) | Preparation de facteur de croissance des cellules t humaines | |
| CH658668A5 (fr) | Procede pour la production de kallikreine humaine. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |